Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
September 05, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the enrollment of the last subject in the Phase 1b study evaluating ARQ-255 for the treatment of alopecia areata.
Allyx Therapeutics Announces First Parkinson’s Disease Patient Treated with ALX-001
September 04, 2024 08:00 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics first patient first patient has been dosed with its lead compound, ALX-001, in new Parkinson's Disease clinical study
PharmaTher Announces Update on FDA New Drug Application for Ketamine
September 04, 2024 08:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced an update for its...
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
September 03, 2024 16:01 ET
|
Athira Pharma, Inc.
LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23) In pre-specified subgroups of patients with moderate Alzheimer’s...
7 Hills Pharma Safely Doses First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod Against aPD-1-resistant Solid Tumors
September 03, 2024 14:02 ET
|
7 Hills Pharma
7 Hills safely doses first cancer patient with alintegimod, a novel selective integrin activator designed to improve the efficacy of checkpoint blockade.
Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)
September 03, 2024 09:00 ET
|
Longeveron
Longeveron announces positive Type C meeting with FDA, clarifying regulatory pathway to BLA submission for Lomecel-B for hypoplastic left heart syndrome.
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
September 03, 2024 07:30 ET
|
23andMe, Inc.
Preliminary data from renal cancer and TMB-H/MSI-H cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Analysis of CD200 as an exploratory tissue-based biomarker associated with...
ImCheck obtient 20,18 millions d’euros de financement public dans le cadre du plan France 2030
August 29, 2024 05:00 ET
|
ImCheck Therapeutics SAS
ImCheck reçoit un financement non-dilutif significatif afin d’accélérer l’avancement de deux programmes innovants, dans le traitement des cancer et des maladies infectieuses, en ligne avec l’ambition...
ImCheck Awarded EUR 20.18 Million from the French Government Through the France 2030 Investment and Innovation Plan
August 29, 2024 05:00 ET
|
ImCheck Therapeutics SAS
FOR IMMEDIATE RELEASE -- ImCheck secures substantial non-dilutive funding to accelerate the progress of two breakthrough programs in cancer and infectious diseases, in support of France's 2030...
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
August 28, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced results from the INTEGUMENT-OLE long-term open-label study of once-daily roflumilast cream 0.05%.